[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100335627":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":74,"centralContacts":78,"locations":79,"responsibleParty":99,"collaborators":101,"id":110,"slug":111,"hasResults":112,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":78,"eligibilityCriteria":116,"healthyVolunteers":112,"sex":117,"minAge":118,"maxAge":78,"enrollmentInfo":119,"targetDuration":78,"studyType":122,"phases":123,"briefSummary":125,"conditions":126,"keywords":78,"overallStatus":81,"whyStopped":78,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},{"fullName":5,"class":6},"OHSU Knight Cancer Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Diagnostic (FMISO, PET\u002FMRI or PET\u002FCT)","EXPERIMENTAL","Participants receive FMISO intravenously (IV). Participants also undergo dynamic PET\u002Fcomputed tomography (CT) or PET\u002FMRI over 120 minutes beginning 1 minute prior to FMISO injection, and static PET\u002FCT or PET\u002FMRI over 20-40 minutes approximately 90 minutes after FMISO injection. Participants then undergo a retest examination within 7 days. Participants may undergo 2 more PET\u002FMRI or PET\u002FCT scans no sooner than every 4 weeks. Supplemental oxygen may be administered to effect MRI signal.",[13,14,15,16,17],"Drug: ¹⁸F-Fluoromisonidazole","Procedure: Computed Tomography","Procedure: Magnetic Resonance Imaging","Procedure: Positron Emission Tomography","Procedure: Oxygen Therapy",[19,28,42,57,68],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","¹⁸F-Fluoromisonidazole","Given IV",[9],[25,26,27],"¹⁸F-MISO","¹⁸F-Misonidazole","FMISO",{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"PROCEDURE","Computed Tomography","Undergo PET\u002FCT",[9],[34,35,36,37,38,39,40,41],"CAT","CAT Scan","Computerized Axial Tomography","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","tomography",{"type":29,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"Magnetic Resonance Imaging","Undergo PET\u002FMRI or PET\u002FCT",[9],[47,48,49,50,51,52,53,54,55,56],"Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance \u002F Nuclear Magnetic Resonance","MR Imaging","MRI","MRI Scan","NMR Imaging","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","NMRI","Nuclear Magnetic Resonance Imaging",{"type":29,"name":58,"description":59,"armGroupLabels":60,"otherNames":61},"Positron Emission Tomography","Undergo PET\u002FMRI",[9],[62,63,64,65,66,67],"Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron Emission Tomography Scan","Positron-Emission Tomography","proton magnetic resonance spectroscopic imaging",{"type":29,"name":69,"description":70,"armGroupLabels":71,"otherNames":72},"Oxygen Therapy","Receive supplemental oxygen",[9],[73],"supplemental oxygen therapy",[75],{"name":76,"affiliation":5,"role":77},"Ramon Barajas","PRINCIPAL_INVESTIGATOR",null,[80],{"facility":5,"status":81,"city":82,"state":83,"zip":84,"country":85,"countryCode":86,"cosmosGeoPoint":87,"geoPoint":92,"contacts":93},"RECRUITING","Portland","Oregon","97239","United States","US",{"type":88,"coordinates":89},"Point",[90,91],-122.67621,45.52345,{"lat":91,"lon":90},[94,98],{"name":76,"role":95,"phone":96,"phoneExt":78,"email":97},"CONTACT","503-494-3408","RADResearch@ohsu.edu",{"name":76,"role":77,"phone":78,"phoneExt":78,"email":78},{"type":77,"investigatorFullName":76,"investigatorTitle":100,"investigatorAffiliation":5,"oldNameTitle":78,"oldOrganization":78},"Principal Investigator",[102,105,107],{"name":103,"class":104},"National Cancer Institute (NCI)","NIH",{"name":106,"class":6},"Oregon Health and Science University",{"name":108,"class":109},"Weill Cornell University","UNKNOWN","100335627","phase-2-feasibility-of-fmiso-in-brain-tumors-100335627",false,"NCT03649880","Feasibility of FMISO in Brain Tumors","Feasibility of [¹⁸F]-Fluoromisonidazole (FMISO) in Assessment of Malignant Brain Tumors","Inclusion Criteria:\n\n* Adult patients (greater than 18 years of age) with a known or suspected intracranial tumor.\n* Able to provide informed written consent and\u002For acceptable surrogate capable of providing consent on the patient's behalf.\n* Legally authorized representative (LAR)-signed informed consent and assent obtained for those subjects identified as decisionally impaired\n* Intracranial lesion known or suspected to be neoplastic greater than 10 mL as assessed by T2\u002Ffluid attenuated inversion recovery (FLAIR) MR imaging.\n* Karnofsky performance score \\> 60 or Eastern Cooperative Oncology Group (ECOG) \\\u003C 3 as assessed by referring clinician.\n* Planning to undergo or previously received therapeutic intervention for the intracranial tumor.\n\nExclusion Criteria:\n\n* Pregnant or breast feeding.\n* Contraindication to PET, MRI, FMISO, or intravenous gadolinium based contrast agents.\n\n  * Claustrophobia.\n  * Weight greater than modality maximum capacity.\n  * Presence of metallic foreign body or implanted medical devices in body not documented as MRI safe according to the Oregon Health \\& Science University (OHSU) Department of Radiology guidelines (including but not limited to cardiac pacemaker, aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants).\n  * Sickle cell disease.\n  * Reduced renal function, as determined by glomerular filtration rate (GFR) \\\u003C 45 mL\u002Fmin\u002F1.73 m\\^2 based on a serum creatinine level obtained per OHSU Department of Radiology and Advanced Imaging Research Center (AIRC) clinical criteria.\n  * History of allergic reactions attributed to compounds of similar chemical or biologic composition to FMISO. An allergic reaction to nitroimidazoles is highly unlikely.\n  * Unsure of pregnancy status as assessed by Department of Radiology and AIRC guidelines.\n  * Subjects for whom supplemental oxygen could be harmful such as people with potential for hypoventilation (end-stage COPD, OSA on CPAP\u002FBi-PAP, etc).\n  * Subjects with a relative contraindication to supplemental oxygen administration will not be provided oxygen but may still participate in the study.\n* Presence of any other co-existing condition that, in the judgment of the principal investigator, might increase the risk to the subject (i.e., plans for hospice or end of life care).\n* Poor peripheral intravenous access evaluated by patient history.\n* Presence of other serious systemic illnesses, including: uncontrolled infection, other uncontrolled malignancy, uncontrolled diabetes type II, or psychiatric\u002Fsocial situations which might impact the endpoint of the study or limit compliance with study requirements.","ALL","18 Years",{"count":120,"type":121},50,"ESTIMATED","INTERVENTIONAL",[124],"PHASE2","This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)\u002Fmagnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET\u002FMRI imaging produces images of the brain and how the body functions. FMISO PET\u002FMRI may help investigators see how much oxygen is getting in the brain tumors.",[127],"Malignant Brain Neoplasm","2025-03-20",{"date":130,"type":131},"2025-03-25","ACTUAL",{"date":133,"type":131},"2019-06-01",{"date":135,"type":121},"2030-01-31",{"name":5,"class":6},1]